Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.84 USD
Change Today +0.0788 / 10.35%
Volume 107.5K
As of 5:20 PM 09/3/15 All times are local (Market data is delayed by at least 15 minutes).

photomedex inc (PHMD) Snapshot

Open
$0.83
Previous Close
$0.76
Day High
$0.84
Day Low
$0.77
52 Week High
09/3/14 - $8.32
52 Week Low
08/24/15 - $0.70
Market Cap
18.5M
Average Volume 10 Days
68.5K
EPS TTM
$-3.50
Shares Outstanding
22.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PHOTOMEDEX INC (PHMD)

photomedex inc (PHMD) Related Businessweek News

No Related Businessweek News Found

photomedex inc (PHMD) Details

PhotoMedex, Inc., a skin health company, provides integrated disease management and aesthetic solutions to dermatologists, professional aestheticians, and consumers in North America, the Asia Pacific, Europe, and South America. The company operates in three segments: Consumer, Physician Recurring, and Professional. It offers products and services that address skin diseases and conditions, including psoriasis, vitiligo, acne, and photo damage. The company also provides a range of home-use devices under the no!no! brand name for various indications, such as hair removal, acne treatment, skin rejuvenation, and lower back pain; and a professional product line for acne clearance, skin tightening, psoriasis care, and hair removal to physician clinics and spas. In addition, it offers Kyrobak that uses technology to treat unspecified, lower back pain; NEOVA skin care products for preventing premature skin aging due to UV-induced DNA damage; and Omnilux light therapy systems to treat wrinkles, acne, minor muscle pain, and pigmented lesions. Further, the company provides Lumière light therapy equipment for use in non-medical applications, as well as a line of topical lotions to enhance the appearance of fine lines, wrinkles, skin tone, and blemishes. Additionally, it develops, manufactures, and sells surgical products, including proprietary free-beam and Contact Laser systems for surgery under the PhotoMedex Surgical Products trade name. PhotoMedex, Inc. was founded in 1980 and is headquartered in Horsham, Pennsylvania.

179 Employees
Last Reported Date: 03/16/15
Founded in 1980

photomedex inc (PHMD) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $468.0K
President, Chief Financial Officer, Treasurer...
Total Annual Compensation: $353.0K
Compensation as of Fiscal Year 2014.

photomedex inc (PHMD) Key Developments

PhotoMedex, Inc. Announces Proposes Settlements in Two Class Action Suits against the Company and its Subsidiaries Approved by the Respective Courts

On August 11, 2015, PhotoMedex, Inc. was notified that the proposed settlements in two class action suits against the company and its subsidiaries had been approved by the respective courts with jurisdiction over those suits. The company had been served on December 20, 2013, with a purported shareholder derivative and class action lawsuit filed in the United States District Court for the Eastern District of Pennsylvania against the company and its two top executives, Dolev Rafaeli, Chief Executive Officer, and Dennis M. McGrath, President and Chief Financial Officer. The action alleged various violations of the Federal securities laws between November 7, 2012 and November 14, 2013, including that the company and its officers made false and misleading statements or failed to disclose material facts concerning the company's business. The plaintiffs sought class action status for the suit, as well as an unspecified amount of monetary damages, pre-and post-judgment interest and attorneys' fees, expert witness fees and other costs. A companion action had also been brought against the company and its two officers in the State of Israel, where the company's shares are traded on the Tel Aviv Stock Exchange. The Eastern District Court has entered an order approving the settlement in this action. The settlement provides a fund of $1.5 million for the benefit of those persons or entities who purchased securities issued by the company during the period November 6, 2012 and November 5, 2013, inclusive. The settlement fund will also pay for plaintiffs' counsel's fees and expenses approved by the Eastern District Court with respect to the action. The company maintains insurance that will help defray the cost of the proposed settlement, and does not expect the settlement to have a material impact on its financial results. The company was also a party in the consolidated action In re LCA-Vision Inc. Shareholder Litigation. The company received notice of this order on March 30, 2015. The action consolidated four separate cases that had been filed in the Common Pleas Court of Hamilton County, Ohio against the company, its subsidiary Gatorade Acquisition Corp., LCA-Vision, Inc., LCA's chief executive officer, Michael J. Celebrezze, and LCA's board of directors over the proposed acquisition of LCA by the company. The Ohio Court has entered an order approving the settlement of all suits in this action. Under the settlement, LCA had published certain additional disclosure statements regarding its acquisition by the Company and its financial statements prior to its shareholder vote on the acquisition, which was held on May 12, 2014. The settlement also provides for the payment of plaintiffs' counsel's fees and expenses with respect to the action. The company believes that LCA maintains insurance that will help defray the cost of the proposed settlement; the company does not expect the proposed settlement to have a material impact on its financial results.

PhotoMedex, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

PhotoMedex, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company's revenues were $19,924,000 compared to $31,799,000 a year ago. Loss from continuing operations before income taxes was $6,456,000 compared to $8,129,000 a year ago. Loss from continuing operations was $2,515,000 compared to $7,220,000 a year ago. Net income was $6,061,000 compared to net loss of $7,480,000 a year ago. Basic and diluted net earnings per share were $0.28 compared to basic and diluted net loss per share of $0.40 a year ago. Basic and diluted net loss per share from continuing operations was $0.12 compared to $0.39 a year ago. EBITDA was $2,642,000 compared to LBITDA of $7,352,000 a year ago. Non-GAAP adjusted loss was $4,497,000 or $0.21 per share compared to $2,122,000 or $0.11 per share a year ago. For the six months, the company's revenues were $40,598,000 compared to $75,813,000 a year ago. Loss from continuing operations before income taxes was $11,414,000 compared to $7,185,000 a year ago. Loss from continuing operations was $7,837,000 compared to $6,197,000 a year ago. Net income was $3,953,000 compared to net loss of $7,825,000 a year ago. Basic and diluted net loss per share was $0.20 compared to basic and diluted net loss per share of $0.42 a year ago. Basic and diluted net loss per share from continuing operations was $0.39 compared to $0.33 a year ago. Net cash provided by operating activities – continuing activities was $3,463,000 compared to net cash used in operating activities of $13,884,000 a year ago. Purchases of property and equipment were $124,000 compared to $242,000 a year ago. LBITDA was $5,992,000 compared to LBITDA of $7,210,000 a year ago. Non-GAAP adjusted loss was $7,021,000 or $0.35 per share compared to non-GAAP adjusted earnings of $415,000 or $0.03 per share a year ago.

PhotoMedex, Inc.(NasdaqGS:PHMD) dropped from Russell 2000 Index

PhotoMedex, Inc. will be removed from Russell 2000 Index

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PHMD:US $0.84 USD +0.0788

PHMD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Biogen Inc $301.63 USD -2.58
Cutera Inc $14.92 USD -0.08
Cynosure Inc $32.60 USD +0.68
Valeant Pharmaceuticals International Inc C$301.25 CAD -6.75
Zeltiq Aesthetics Inc $31.87 USD -0.50
View Industry Companies
 

Industry Analysis

PHMD

Industry Average

Valuation PHMD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.1x
Price/Book 0.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PHOTOMEDEX INC, please visit www.photomedex.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.